Carcinoembryonic Antigen-Antibody Complexes in a Patient with Colonic Carcinoma and Nephrotic Syndrome

Costanza, Mary E.; Pinn, Vivian W.; Schwartz, Robert S.; Nathanson, Larry

doi:10.1056/nejm197309062891007

Cited by 187 publications

(56 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No specific anti-CEA activity was found, and we wonder whether such activity exists at all. The only evidence that is cited for anti-CEA activity in human sera is the work of Gold & Gold (1973) and Gold et al (1972) and the demonstration of CEA in immune complex nephropathy in a patient with colon tumour (Costanza et al, 1973). However, both may be related to the phenomenon described here.…”

Section: Discussionmentioning

confidence: 79%

Antibody-dependent cellular cytotoxicity to human colon-tumour cells. II. Analysis of the antigens involved

Shoham¹,

Cohen²

1979

Br J Cancer

View full text Add to dashboard Cite

Summary.-The relationship between carcinoembryonic antigen (CEA) and A antigenic determinants on the cell surface of colon-tumour cells was studied by the ADCC assay. Antiserum prepared in 2 rabbits to an undecapeptide analogous to the amino terminal of CEA(l -11) was found by us either to participate in (Rabbit 2) or specifically inhibit (Rabbit 1) ADCC. The binding spectra of these two antisera and of antiserum to the whole CEA molecule were similar. All of them react with A and non-A colon-tumour cells as well as red blood cells of Type A (RBC-A) and their activity was completely absorbed on RBC-A but not on B or 0. 0-type, ADCCreactive human sera always react with A-type colon-tumour cells and RBC-A, and some of them with non-A colon-tumour cells also. The degree of inhibition of their reactivity by anti-CEA(l -11) RI varied between sera, from none to almost a complete inhibition, and is not related to whether the serum is of cancer or non-cancer origin. Non-reactive 0-type sera contain anti-A activity demonstrable by haemagglutination and immunofluorescence. However, they cannot participate in ADCC reaction nor inhibit it. The sera, which contain lymphocyte-dependent antibody to A-type colon-tumour cells, lysed RBC-A, without the addition of lymphocytes or complement, in an immunologically specific way. It is concluded that the reactivity seen in our ADCC system is related to a determinant common to A and CEA (and maybe to other normal cross-reacting antigens) which most probably resides in the amino terminal part of these molecules. This determinant elicits the production of lymphocyte-dependent antibodies in about 50o/ of people with blood group 0. Thus, the amino terminal part of CEA is not a tumour-specific part of the CEA molecule. No specific anti-tumour activity was found in patients' serum by this method, and claims for its demonstration by other methods may well be related to the non-specific activity observed here.

show abstract

Section: Discussionmentioning

confidence: 79%

Antibody-dependent cellular cytotoxicity to human colon-tumour cells. II. Analysis of the antigens involved

Shoham¹,

Cohen²

1979

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Although Hodgkin's disease is the most cancer (Couser et al, 1974;Lewis et al, 1971;Wakashin et al, 1980;Weksler et al, 1974;Constanza et al, 1973) and the probable cause of proliferative lesions (Jermanovich et al, 1982). The pathogenesis of both tumour associated and idiopathic MCN is, by contrast, obscure.…”

Section: Discussionmentioning

confidence: 99%

Minimal change nephropathy associated with anaplastic carcinoma of bronchus

1987

Lung Cancer

View full text Add to dashboard Cite

“…The occurrence of circulating immune complexes in cancer patients has been suggested first by the demonstration of serum blocking factors possibly related to immune complexes, and secondly by the direct detection of material similar to antigenantibody complexes in some patients with various types of malignancy (18,(20)(21)(22)(23)(24)(25)(26)(27)(28)39). In human leukemia, the presence of immune complexes has been suggested by the finding of renal glomerular deposits of Ig and complement in a few cases (29).…”

Section: Discussionmentioning

confidence: 99%

“…There is evidence that serum blocking factors may consist of immune complexes (16)(17)(18)(19). Furthermore, several studies have indicated that antigen-antibody complexes, possibly related to the tumor, may circulate in blood (18,(20)(21)(22)(23)(24) or be deposited in tissues (25)(26)(27)(28) of patients with different types of malignancy, including leukemia (29 The present study was carried out, using the [125I]-Clq-binding test (30) and the Raji cell radioassay (23), to determine the incidence of circulating immune complexes in leukemia and to investigate their relationship to clinical and biological features of the disease and to prognosis. The serum Clq-binding material which was detected was further characterized by immunochemical and physical analysis.…”

Section: Introductionmentioning

confidence: 99%